A novel skeleton type cytochalasin and its application in preparing drugs with anti-tumor activity

By isolating and identifying a novel five-ring system cytochalasin boerelasin B from the endophytic fungus of Hubei Fritillaria B, the problem of lack of effective anti-tumor active compounds in the prior art was solved, and five types of people were realized The significant cytotoxic activity of tumor-derived cells has potential drug application value.

CN116554187BActive Publication Date: 2024-11-26SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310570234.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-26
Estimated Expiration
2043-05-19

AI Technical Summary

Technical Problem

The lack of effective anti-tumor active compounds in the prior art, especially the use of cytochalasin-like compounds isolated from the endophytes of Hubei Fritillaria is not fully developed.

Method used

A novel five-ring system cell relaxin boerelasin B was isolated and extracted from the endophytic fungus of Hubei Fritillaria B.exigua, and its structure was determined through nuclear magnetic resonance spectrum and other means, verifying that it has different characteristics for the five human tumor cells. degree of cytotoxic activity.

Benefits of technology

boerelasin B showed significant anti-tumor activity, with significant cytotoxic activity on human liver cancer, lung cancer, leukemia, breast cancer and colon cancer cells, with an IC50 value ranging from 10μM to 30.56μM, which has potential pharmaceutical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004238257830000021
    Figure BDA0004238257830000021
  • Figure BDA0004238257830000051
    Figure BDA0004238257830000051
  • Figure BDA0004238257830000061
    Figure BDA0004238257830000061
Patent Text Reader

Abstract

The present invention relates to the technical field of pharmaceutical chemistry and specifically discloses an endophytic fungus isolated from Hubei Fritillaria thunbergii. Small Bohemia A novel cytochalasin compound with a 5 / 6 / 5 / 6 / 8 pentacyclic system was isolated from the raw material of the plant, and it was named boerelasin B. The MTS method was used to evaluate its cytotoxic activity against 5 types of human tumor cells. The biological activity evaluation showed that the compound had different degrees of cytotoxic activity against the 5 types of human tumor cells, among which it showed significant cytotoxic activity against SMMC-7721 (human liver cancer cells) and A549 (human lung cancer cells). IC 50 <10 μ M; Its cytotoxic activity against HL‑60 (human leukemia cells) and MCF‑7 (human breast cancer cells) is comparable to that of the positive control drug cisplatin; It has good inhibitory activity against SW480 (human colon cancer cells).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicine and chemistry, and in particular to a cytochalasin compound derived from an endophytic fungus of Hubei Fritillaria thunbergii B. exigua and an application thereof in preparing a drug with anti-tumor activity. Background Art

[0002] Fritillaria is a perennial herb, its flowers are for gardening and its underground bulbs are for medicinal purposes. It is named after the shape of its bulbs. The "Compendium of Materia Medica" says: "It looks like a bunch of clam shells", so it is called Fritillaria. Hubei Fritillaria is one of the native Fritillaria in China and is a local medicinal material in Hubei Province. It has the effects of resolving phlegm and relieving cough, detoxifying and dispersing nodules. It is mainly used to treat exogenous wind-heat cough and phlegm-heat cough. It is a daily essential Chinese medicine for ordinary people and an important economic crop in Enshi Tujia and Miao Autonomous Prefecture, Hubei Province.

[0003] Endophytic fungi live in healthy plant tissues and organs, and are in a mutually beneficial symbiotic equilibrium with plants. The synthetic pathways of endophytic fungi themselves are rich, diverse, and ever-changing. They provide a series of new compounds with complex structures that are difficult to obtain through artificial chemical synthesis. They are an important source of novel structurally active natural products and clinical drugs. Many pesticides, anticancer drugs, and antibacterial drugs are directly or indirectly derived from endophytic fungi. In recent years, natural product researchers have isolated different endophytic fungi from the bulbs of various Fritillaria, and studied the chemical composition and biological activity of the isolated endophytic fungi. For example: all fermentation filtrates of endophytic fungi belonging to the genus Fusarium showed antioxidant activity; three new hybrid polyketide compounds were isolated from the solid fermentation products of endophytic fungi of Hubei Fritillaria, and through biological activity experiments, it was found that their compounds had significant cytotoxic activity against mouse lymphoma cells L5178Y; four endophytic fungi were isolated and identified from Hubei Fritillaria, and it was found that the antibacterial activity of the secondary metabolites of three of them was better than that of the bacterium Pseudomonas sp.BM-X-6, and the secondary metabolites of Arthrinium sp.BM-Z-5 had the broadest antibacterial spectrum. This study shows that endophytic fungi of Hubei Fritillaria have a certain resistance to biological persecution.

[0004] Based on the advantages of rich resources, wide variety, short culture cycle, high feasibility of genetic manipulation of endophytic fungi, and the fact that cytochalasin compounds have multiple biological activities, such as anti-tumor, anti-bacterial, anti-inflammatory, and antioxidant, the applicant explored the anti-tumor activity of a cytochalasin isolated from the endophytic fungi of Fritillaria thunbergii. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention aims to provide a cytochalasin and its use in the preparation of a drug with anti-tumor activity.

[0006] A cytochalasin with anti-tumor activity, the structural formula of which is as follows:

[0007]

[0008] Molecular formula: C 29 H 35 NO4

[0009] Name: boerelasin B

[0010] Another object of the present invention is to verify that the cytochalasin boerelasin B has different degrees of cytotoxic activity against five types of human tumor cells.

[0011] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0012] 1. The present invention discloses a novel skeleton type cytochalasin with a 5 / 6 / 5 / 6 / 8 five-ring system derived from the endophytic fungus B. exigua of Hubei Fritillaria.

[0013] 2. The present invention provides a cytochalasin with anti-tumor activity, which has different degrees of cytotoxic activity against 5 types of human tumor cells.

[0014] 3. The cytochalasin for pharmaceutical use to be protected by the present invention can be obtained by extraction and purification from endophytic fungi in plants, and has the advantages of short culture cycle, high operational feasibility, no chemical pollution, and green environmental protection. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is the hydrogen spectrum (800 MHz, CDCl3) of the compound prepared in Example 1 in the specific implementation mode;

[0016] Figure 2 The carbon spectrum (201 MHz, CDCl3) and DEPT diagram of the compound prepared in Example 1 of the specific implementation manner;

[0017] Figure 3 It is the HMQC diagram of the compound prepared in Example 1 in the specific embodiment;

[0018] Figure 4 It is the HMBC diagram of the compound prepared in Example 1 in the specific implementation mode;

[0019] Figure 5 The compound prepared in Example 1 in the specific embodiment 1 H- 1 H COSY diagram;

[0020] Figure 6ROESY diagram of the compound prepared in Example 1 in the specific embodiment;

[0021] Figure 7 HR-ESI-MS chart of the compound prepared in Example 1 in the specific embodiment;

[0022] Figure 8 Measured ECD and calculated ECD diagram of the compound prepared in Example 1 in the specific implementation manner. DETAILED DESCRIPTION

[0023] In order to make the invention purpose and invention content of this application more clearly presented, the applicant will provide a clear and complete description of the technical solution of the present invention in conjunction with specific embodiments below.

[0024] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0025] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0026] Embodiment 1:

[0027] The raw material, the endophytic fungus Boeremia exigua (abbreviated as: B. exigua), was isolated from the roots of fresh plants of Hubei Fritillaria. The Fritillaria was collected from Shuanghe Community, Xintang Township, Enshi City, Enshi Tujia and Miao Autonomous Prefecture, Hubei Province. The strain was self-numbered Bei 21. The ITS sequence determination results showed that the maximum similarity between the sequence and Boeremia exigua was as high as 100%, and the gene bank accession number was MT154621.1. Therefore, it was identified as Boeremia exigua. The strain was deposited in the Microbial Strain Bank of the School of Pharmacy of South-Central University for Nationalities (has been published, see: Lv Xiao, Ye Ke, Ma Xujun et al. Study on the chemical composition and anti-inflammatory activity of the endophytic fungus Boeremia exigua in Hubei Fritillaria [J]. Journal of South-Central University for Nationalities (Natural Science Edition), 2022, 41(2): 174-179).

[0028] The specific separation process of the above-mentioned Hubei Fritillaria endophytic fungus Bei 21 is as follows: take Hubei Fritillaria endophytic fungus (root of fresh plant), rinse it with tap water and cut it into small pieces, rinse it with 75% V / V ethanol for 60s, rinse it with sterile water 3 times, soak it in 0.1% mercuric chloride (1g mercuric chloride dissolved in 1000g distilled water) for 40s, rinse it with sterile water again 3 times, dry it with high-pressure sterilized filter paper, cut off the incisions at both ends of the Hubei Fritillaria root and cut it from the middle, and inoculate these small pieces on potato dextrose agar (PDA) medium containing penicillin-streptomycin mixture under sterile conditions, and place it in a constant temperature incubator at 25°C for culture. After the fungal hyphae grow out, pick the hyphae for purification and culture to obtain a single strain, transfer the obtained single strain to a test tube filled with PDA medium, and store it in a 4°C refrigerator.

[0029] The strain Bei 21 was fermented by oat solid fermentation: the strain was activated, the test tube was taken out of the refrigerator, and placed in a sterile room temperature environment for 1 hour, and then a bacterial block with a diameter of about 5 mm was taken from the test tube under a sterile operating table and inoculated on a flat PDA medium. After growing for about 7 days, the colony was full of PDA and was set aside. The oat culture medium ratio: 50g oats / bottle, 50mL distilled water / bottle, placed in a 500mL culture bottle, sterilized at 120℃ for 20 minutes, cooled, and picked from the flat PDA medium in a sterile environment. The bacterial block with a diameter of 5 mm was inoculated on the oat culture medium, a total of 272 bottles, and the culture conditions were dark culture at 25℃ for 35 days.

[0030] The separation and purification process of the compound cytochalasin described in the claims and the invention content of the specification: the oat solid culture medium (a total of 15 kg) after fermentation is crushed and soaked in an organic mixed reagent (dichloromethane-methanol = 1:1, v / v) for 5 times, each time for 24 hours. Centrifuge after each soaking, combine the extracts after 5 centrifugations, concentrate under reduced pressure and evaporate the solvent, add a small amount of water to dissolve, extract 5 times with ethyl acetate, and then combine the ethyl acetate parts and concentrate under reduced pressure to obtain 418.77g of crude extract. Use 80-100 mesh normal phase silica gel chromatography column chromatography (CH2Cl2-MeOH: 100:0, 50:1, 20:1, 10:1, 5:1, v / v) gradient elution, and use thin layer chromatography (developing solvent is chloroform: methanol = 10:1, v / v; thin layer chromatography silica gel plate, Qingdao Ocean Chemical Plant) to detect and develop color, and crudely segment to obtain five components A-E.

[0031] Component C (the component eluted when the volume ratio of dichloromethane / methanol is 20:1, the amount of eluent used is 5 column volumes, 15.5g) was subjected to high-performance medium-pressure liquid preparative chromatography (Biotage SP1, reverse phase filler material: RP-18, 20-45μm, Fuji Silysia Chemical Ltd., Japan) in a methanol-water system (methanol / water = 50:50, 60:40, 70:30, 80:20, 100:0, v / v), with a flow rate of 20mL / min for gradient elution, and the elution time for each ratio was 60min. Thin layer chromatography (developing solvent is chloroform: methanol = 20:1, v / v; thin layer chromatography silica gel plate, Qingdao Ocean Chemical Plant) was used for detection and color development, and the same or similar components were combined, and finally combined into eight subcomponents, which were labeled C1-C8 in order from small to large polarity. The C6 component (the component eluted when the volume ratio of methanol to water is 60:40, 3.6 g) was passed through a normal phase silica gel column (200-300 mesh) and gradient eluted with a dichloromethane-methanol system (dichloromethane / methanol = 20:1, 10:1, 1:1, v / v), and detected and developed by thin layer chromatography (developing solvent: chloroform: methanol = 10:1, v / v; thin layer chromatography silica gel plate, Qingdao Ocean Chemical Plant). The same or similar components were combined to obtain 5 subcomponents, which were labeled C6-1 to C6-5 in ascending order of polarity. C6-2 (the component eluted when the volume ratio of dichloromethane / methanol is 10:1, the amount of eluent used is 5 column volumes, 68 mg) was eluted with methanol (the amount of methanol used is 10 column volumes) on Sephadex LH-20 gel column chromatography (Pharmacia Fine Chemical Co., Ltd., Sweden), and the resulting 24.7 mg product was subjected to high performance liquid preparative chromatography (Agilent 1260; chromatographic column: Agilent Zorbax SB-C18, specifications: 9.4 mm×150 mm, 5 μm; acetonitrile-water: 45:55-55:45, v / v; flow rate: 4 mL / min) with gradient elution for 25 min to prepare 1.5 mg of the compound of the present invention (retention time is 16.6 min).

[0032] Structural identification of the compound: The compound cytochalasin prepared in Example 1 was dissolved in 0.5 mL of deuterated chloroform, transferred to a nuclear magnetic resonance tube using a 200 μL pipette, and the hydrogen spectrum, carbon spectrum, and two-dimensional spectrum (such as Figure 1-6 ) to determine its relative configuration, and then calculate the ECD (such as Figure 8 ) The stereo configuration of the compound was determined. The structure of the compound was solved by integrating various physical and chemical data and named boerelasin B.

[0033] The obtained NMR data of cytochalasin:

[0034]

[0035] Other physical and chemical data:

[0036] Appearance: White amorphous powder, according to high resolution mass spectrometry HRESIMS ([M+H] + , m / z 462.2640).

[0037] According to the above test results, the structural formula of the compound obtained in this example is confirmed to be:

[0038]

[0039] Molecular formula: C 29 H 35 NO4

[0040] Example 2: MTS detection of cell viability

[0041] Principle of MTS method for detecting cell activity:

[0042] MTS is a new MTT analogue, the full name is 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliu m, and it is a yellow dye. Succinate dehydrogenase in the mitochondria of living cells can metabolize and reduce MTS to generate soluble formazan compounds, and the content of formazan can be measured at 490nm using an enzyme marker. Under normal circumstances, the amount of formazan generated is proportional to the number of living cells, so the number of living cells can be inferred based on the optical density OD value.

[0043] Experimental methods:

[0044] 1. Cell inoculation: Five tumor cells (Kunming Institute of Botany, Chinese Academy of Sciences) were prepared into single cell suspensions using DMEM culture medium containing 10% fetal bovine serum. Approximately 5,000 cells were inoculated into 96-well plates with a volume of 100 μL per well. The cells were inoculated and cultured 12 to 24 hours in advance.

[0045] 2. Add the solution of the compound to be tested: dissolve the compound obtained in Example 1, cisplatin and paclitaxel in DMSO respectively, and screen the compound at concentrations of 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.62 μM, 0.31 μM, 0.16 μM and 0.08 μM. The final volume of each well is 200 μL, and 3 replicate wells are set for each treatment.

[0046] 3. Color development: After culturing at 37 degrees Celsius for 48 hours, discard all the culture medium in the wells of adherent cells (A549, SMMC-7721, MCF-7, SW480), add 20 μL of MTS solution and 100 μL of culture medium (DMEM culture medium containing 10% fetal bovine serum) to each well; discard 100 μL of culture supernatant of suspension cells (HL-60), add 20 μL of MTS solution to each well; set up 3 blank replicate wells (a mixture of 20 μL MTS solution and 100 μL culture medium), continue incubation for 2 to 4 hours, allow the reaction to proceed fully, and then measure the light absorbance value.

[0047] 4. Colorimetry: Select 490nm wavelength, use a multifunctional microplate reader (MULTISKAN FC) to read the light absorption value of each well, record the results, and after data processing, draw a cell growth curve with concentration as the horizontal axis and cell survival rate as the vertical axis. Apply the two-point method (Reed and Muench method) to calculate the IC of the compound 50 value.

[0048] 5. Positive control compounds: Cisplatin and Paclitaxel were used as positive control compounds for each experiment. The cell growth curve was drawn with the concentration as the horizontal axis and the cell survival rate as the vertical axis. The IC of the compound was calculated using the two-point method (Reed and Muench method). 50 The calculation formula of cell survival rate is: cell survival rate % = drug group / blank group × 100%.

[0049] Experimental results:

[0050] The results showed that the compound boerelasin B of the present invention exhibited significant cytotoxic activity against SMMC-7721 (human liver cancer cells) and A549 (human lung cancer cells), IC 50 <10μM, has significant inhibitory activity against HL-60 (human leukemia cells) and MCF-7 (human breast cancer cells), IC 50 The values ​​were 14.16μM and 19.21μM, which were comparable to the positive control drug cisplatin; they had good inhibitory activity against SW480 (human colon cancer cells), IC 50 The value is 30.56μM.

[0051] Table 1: IC of boerelasin B, cisplatin and paclitaxel against five tumor cell types 50 (μM) value

[0052]

Claims

1. A novel skeleton type cytochalasin compound, the structural formula of the compound is:

2. A method for preparing the compound according to claim 1, characterized in that: The following steps are involved: 1) using oat solid fermentation to expand the culture of the endophytic fungus B. exigua of Hubei Fritillaria, then crushing the fermented oat solid culture medium and soaking and extracting it with an organic mixed reagent, concentrating the extract to dryness, then adding water to dissolve it, and extracting it with ethyl acetate; 2) Separating the ethyl acetate extract by silica gel column to obtain five components of AE; 3) separating the C component by medium pressure liquid preparative chromatography to obtain eight subcomponents C1-C8; 4) Separating the C6 component by silica gel column to obtain five sub-components C6-1 to C6-5; 5) After the C6-2 component is separated by gel column chromatography, the obtained product is purified by high performance liquid phase preparative chromatography to obtain the compound; The organic mixed reagent in step 1) is a dichloromethane-methanol mixed solvent with a volume ratio of 1:1; Oatmeal culture medium ratio: solid-liquid ratio of oatmeal to distilled water is 1g:1mL, sterilized at 120℃ for later use; The conditions for the expansion culture were as follows: dark culture at 25°C for 35 days; The conditions for silica gel column separation in step 2) include: using dichloromethane-methanol as the eluent, eluting in a volume ratio of 100:0, 50:1, 20:1, 10:1 and 5:1 in sequence, and TLC detection to obtain five elution components, wherein the developing solvent is chloroform:methanol=10:1, v / v; The conditions for medium pressure liquid preparative chromatography separation in step 3) include: RP-18 chromatographic column, methanol-water as eluent, elution in volume ratios of 50:50, 60:40, 70:30, 80:20 and 100:0, flow rate of 20 mL / min, elution time of each ratio of 60 min, TLC detection, eight elution subcomponents, wherein the developing solvent is chloroform: methanol = 20:1, v / v; The conditions for silica gel column separation in step 4) include: using dichloromethane-methanol as eluent, eluting in a volume ratio of 20:1, 10:1, and 1:1 in sequence, and TLC detection to obtain five elution components, wherein the developing solvent is chloroform:methanol=10:1, v / v; The gel column chromatography in step 5) uses methanol as the eluent; The conditions of the high performance liquid preparative chromatography in step 5) include: a C18 chromatographic column, a mixed solvent of acetonitrile and water as the eluent, a gradient elution for 25 min at an initial volume ratio of acetonitrile to water of 45:55 and a final volume ratio of 55:45, and a flow rate of 4 mL / min.

3. Use of the compound according to claim 1 in the preparation of a drug for inhibiting the growth of tumor cells SMMC-7721, A549, HL-60, MCF-7 and / or SW480.